Cap Vorinostat


Indications and Reactions:

Role Indications Reactions
Primary
Multiple Myeloma 31.5%
Non-small Cell Lung Cancer 30.5%
Mycosis Fungoides 8.1%
Myelodysplastic Syndrome 6.8%
Acute Myeloid Leukaemia 4.4%
Febrile Neutropenia 3.0%
B-cell Lymphoma 2.3%
Lung Neoplasm Malignant 1.6%
Adenocarcinoma 1.5%
Breast Cancer 1.5%
Contraception 1.3%
Malignant Melanoma 1.3%
Nodal Marginal Zone B-cell Lymphoma 1.1%
Myeloma Recurrence 1.0%
Sarcoma Metastatic 1.0%
Hodgkin's Disease 0.8%
Ovarian Epithelial Cancer Recurrent 0.8%
Mesothelioma 0.6%
Chronic Lymphocytic Leukaemia 0.5%
Hypertension 0.5%
Thrombocytopenia 21.6%
White Blood Cell Count Decreased 17.2%
Weight Decreased 13.2%
Vomiting 9.3%
Pneumonia 4.4%
Syncope 3.1%
Platelet Count Decreased 2.6%
Pulmonary Embolism 2.6%
Treatment Noncompliance 2.6%
Venous Thrombosis Limb 2.6%
Vith Nerve Paralysis 2.6%
Diarrhoea 2.2%
Febrile Neutropenia 2.2%
Staphylococcal Infection 2.2%
Urinary Retention 2.2%
Venous Aneurysm 2.2%
Asthenia 1.8%
Dyspnoea 1.8%
Peripheral Ischaemia 1.8%
Renal Failure 1.8%
Secondary
Multiple Myeloma 45.1%
Febrile Neutropenia 18.3%
Adenocarcinoma 8.5%
Acute Myeloid Leukaemia 5.6%
Medulloblastoma 5.6%
Myelodysplastic Syndrome 4.2%
Product Used For Unknown Indication 4.2%
B-cell Lymphoma 2.8%
Nausea 2.8%
Glioblastoma Multiforme 1.4%
Papillary Thyroid Cancer 1.4%
Sepsis 27.3%
Pneumonia 18.2%
Chest Pain 4.5%
Febrile Neutropenia 4.5%
Hypotension 4.5%
Lobar Pneumonia 4.5%
Lung Infection 4.5%
Neoplasm Malignant 4.5%
Pulmonary Oedema 4.5%
Thrombocytopenia 4.5%
Urinary Retention 4.5%
Urinary Tract Infection 4.5%
Urine Output Decreased 4.5%
White Blood Cells Urine Positive 4.5%

Drug Data